From November 4th to 6th, the 3rd Taishan Pharmaceutical Forum and the 2023-2024 Pharmaceutical Industry Information Release Conference were held in Jinan, Shandong. With its good operating performance and strong innovation capabilities, Jiudian Pharmaceuticalwas listed in the "Top 100 Companies in Pharmaceutical Industry Revenue" and "Top 50 Companies in Pharmaceutical Industry Growth Rate" in 2023-2024.

The 2023-2024 Pharmaceutical Industry Information Release Conference announced 12 important lists, including "Top 100 Pharmaceutical Industry Business Revenue Companies", "Top 100 Pharmaceutical Commercial Business Revenue Companies", "Top 50 Pharmaceutical Industry Growth Rate Companies", "Top 50 Pharmaceutical Industry R&D Companies", etc. These series of lists are comprehensive evaluation by a selection team composed of domestic experts and a number of authoritative media, following the principles of open solicitation, based on objective data, strict screening, and fair selection. There are the most influential and credible series of lists in the domestic pharmaceutical industry.

According to the selection criteria, the "Top 100 Pharmaceutical Industry Business Revenue Companies" list is mainly ranked based on the company's annual turnover, and the "Top 50 Pharmaceutical Industry Growth Rate Companies" list is based on the company's compound growth rate of turnover in the past three years as the core indicators. Jiudian Pharmaceutical was listed on these two heavyweight lists at the same time, fully demonstrating the industry and the society's high recognition of its comprehensive strength and development prospects.

In the first half of this year, the company successfully ranked 65th in the "2024 China Pharmaceutical R&D Comprehensive Strength Ranking TOP100" with its breakthrough achievements in R&D and innovation in the fields of chemical drugs and traditional Chinese medicine; won the 50th place in the "2024 China Chemical Drug R&D Strength Ranking TOP100"; won the 25th place in the "2024 China Traditional Chinese Medicine R&D Strength Ranking TOP50"; and ranked 51st in the "2023 China Chemical Pharmaceutical Enterprise Top100 Ranking", an increase of 19 places from 2022.